Elevation Oncology, Inc. (ELEV)

Market Cap	23.77M
Revenue (ttm)	n/a
Net Income (ttm)	-85.66M
Shares Out	23.30M
EPS (ttm)	-3.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	391
Open	1.00
Previous Close	1.00
Day's Range	1.00 - 1.02
52-Week Range	0.72 - 5.20
Beta	n/a
Analysts	Buy
Price Target	4.93 (+383.33%)
Earnings Date	Mar 2, 2023

About ELEV

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 48
• Stock Exchange: NASDAQ
• Ticker Symbol: ELEV

Analyst Forecast

According to 11 analysts, the average rating for ELEV stock is "Buy." The 12-month stock price forecast is $4.93, which is an increase of 383.33% from the latest price.

Price Target

$4.93

(383.33% upside)

Analyst Consensus: Buy